Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg (CRSP)

RomoloTavani Investment Overview Crispr Therapeutics AG (NASDAQ:CRSP), the first company to secure U.S. approval for a CRISPR (“clustered, regularly interspaced, short palindromic repeats”) based gene editing therapy, Casgevy, indicated for Sickle Cell Disease (“SCD”) and Transfusion Dependent Beta Thalassemia (“TDT”), reported its Q1 2024 earnings yesterday after the bell. The reality is that Crispr Therapeutics…

Read More

CRISPR Gene Editing: Beam Therapeutics

Andy/iStock via Getty Images In my third edition of my CRISPR series (see article 1 (an overview of CRISPR-Cas9) and article 2 (a comparison of CRSP and NTLA)), I want to focus on Beam Therapeutics (NASDAQ:BEAM), which is a favorite amongst investors because it uses what many believe to be a better version of gene…

Read More